In this context, Rezvani’s group generated CAR-CD19+ NK cells that not only persist and mediate an efficient killing of primary CLL cells in vitro but also incorporate safety measures to limit toxicity [301]. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.